{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:30Z","timestamp":1792979910938,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103430"],"award-info":[{"award-number":["P20GM103430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"F.W. thanks the Rhode Island Foundation for a Medical Research Grant and support of the Rhode Island Life Science Hub."},{"name":"N.L.P. acknowledges the University of Rhode Island for internship funding."},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA034992"],"award-info":[{"award-number":["CA034992"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A common mechanism by which cancer cells acquire resistance to chemotherapeutics is through the overexpression of efflux pumps, enabling the removal of cytotoxic agents, such as anthracycline drugs. However, platinum anticancer agents that crosslink DNA and interact with proteins are poor efflux pump substrates. Here, we design dual warhead drug conjugates by tethering a platinum pharmacophore to the doxorubicin backbone. These drug conjugates retain the anticancer activity of anthracyclines and exhibit the ability to both circumvent drug efflux and delay the acquisition of drug resistance. In vivo experiments demonstrate that such drug conjugates extend survival in a preclinical\u00a0organoid-based model of metastatic colon cancer\u00a0in mice. Mechanistic studies indicate that these drug conjugates overcome resistance through covalent platinum-protein interactions, leading to significantly improved drug retention and alteration of subcellular drug distribution. This application of platinum offers many opportunities to confront issues related to chemoresistance and alternative pathways for augmenting conventional chemotherapeutics.<\/jats:p>","DOI":"10.1038\/s41467-025-64295-0","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:26:35Z","timestamp":1760955995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Leveraging platinum-protein interactions to overcome chemoresistance"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-6858","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0759-7220","authenticated-orcid":false,"given":"Jonathan","family":"Braverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozen","family":"Leylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7494-359X","authenticated-orcid":false,"given":"Nicholas L.","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-4492","authenticated-orcid":false,"given":"Daniel S.","family":"Honeycutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8651-7392","authenticated-orcid":false,"given":"Brian","family":"Pallares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7259-0948","authenticated-orcid":false,"given":"Daiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1957-355X","authenticated-orcid":false,"given":"Jason M.","family":"Mrosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0912-863X","authenticated-orcid":false,"given":"Camellia S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Griadunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7778-0821","authenticated-orcid":false,"given":"William K.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8004-3769","authenticated-orcid":false,"given":"Jacob M.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-2163","authenticated-orcid":false,"given":"Michael T.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Lippard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-4612","authenticated-orcid":false,"given":"\u00d6mer H.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"64295_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64295_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","volume":"15","author":"BC Shaffer","year":"2012","unstructured":"Shaffer, B. C. et al. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist. Updates 15, 62 (2012).","journal-title":"Drug Resist. Updates"},{"key":"64295_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"A-M Patch","year":"2015","unstructured":"Patch, A.-M. et al. Whole\u2013genome characterization of chemoresistant ovarian cancer. Nature 521, 489 (2015).","journal-title":"Nature"},{"key":"64295_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"64295_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152 (1976).","journal-title":"Biochim. Biophys. Acta"},{"key":"64295_CR6","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1126\/science.1168750","volume":"323","author":"SG Aller","year":"2009","unstructured":"Aller, S. G. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718 (2009).","journal-title":"Science"},{"key":"64295_CR7","doi-asserted-by":"publisher","first-page":"11108","DOI":"10.1200\/jco.2015.33.15_suppl.11108","volume":"33","author":"R Feldman","year":"2015","unstructured":"Feldman, R., Abbott, B. L., Reddy, S. K. & Castro, M. Drug efflux pump expression in 50,000 molecularly-profiled cancer patients. J. Clin. Oncol. 33, 11108 (2015).","journal-title":"J. Clin. Oncol."},{"key":"64295_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1126\/science.6372095","volume":"224","author":"A Rogan","year":"1984","unstructured":"Rogan, A., Hamilton, T., Young, R., Klecker, R. & Ozols, R. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224, 994 (1984).","journal-title":"Science"},{"key":"64295_CR9","first-page":"237","volume":"1775","author":"J-P Gillet","year":"2007","unstructured":"Gillet, J.-P., Efferth, T. & Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta. 1775, 237 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"64295_CR10","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1182\/blood-2010-09-304311","volume":"116","author":"E Libby","year":"2010","unstructured":"Libby, E. & Hromas, R. Dismounting the MDR horse. Blood 116, 4037 (2010).","journal-title":"Blood"},{"key":"64295_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1042\/bse0500209","volume":"50","author":"A Tamaki","year":"2011","unstructured":"Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W. & Bates, S. E. The controversial role of ABC transporters in clinical oncology. Essays Biochem 50, 209 (2011).","journal-title":"Essays Biochem"},{"key":"64295_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1042\/BST20150131","volume":"43","author":"R Callaghan","year":"2015","unstructured":"Callaghan, R. Providing a molecular mechanism for P-glycoprotein; why would I bother?. Biochem. Soc. Trans. 43, 995 (2015).","journal-title":"Biochem. Soc. Trans."},{"key":"64295_CR13","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/092986712800167392","volume":"19","author":"A Palmeira","year":"2012","unstructured":"Palmeira, A. et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem. 19, 1946 (2012).","journal-title":"Curr. Med. Chem."},{"key":"64295_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/15680096113139990076","volume":"13","author":"Z Binkhathlan","year":"2013","unstructured":"Binkhathlan, Z. & Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr. Cancer Drug Targets 13, 326 (2013).","journal-title":"Curr. Cancer Drug Targets"},{"key":"64295_CR15","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-04-0212","volume":"11","author":"MHGP Raaijmakers","year":"2005","unstructured":"Raaijmakers, M. H. G. P. et al. Breast cancer resistance protein in drug resistance of primitive CD34+38\u2212 cells in acute myeloid leukemia. Clin. Cancer Res. 11, 2436 (2005).","journal-title":"Clin. Cancer Res."},{"key":"64295_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"D-W Shen","year":"2012","unstructured":"Shen, D.-W., Pouliot, L. M., Hall, M. D. & Gottesman, M. M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64, 706 (2012).","journal-title":"Pharmacol. Rev."},{"key":"64295_CR17","doi-asserted-by":"publisher","first-page":"20116","DOI":"10.1016\/S0021-9258(20)80702-9","volume":"268","author":"T Ishikawa","year":"1993","unstructured":"Ishikawa, T. & Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268, 20116 (1993).","journal-title":"J. Biol. Chem."},{"key":"64295_CR18","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1073\/pnas.73.8.2536","volume":"73","author":"KG Strothkamp","year":"1976","unstructured":"Strothkamp, K. G. & Lippard, S. J. Platinum binds selectively to phosphorothioate groups in mono- and polynucleotides: a general method for heavy metal staining of specific nucleotides. Proc. Natl Acad. Sci. USA 73, 2536 (1976).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64295_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/ic950973d","volume":"35","author":"KJ Barnham","year":"1996","unstructured":"Barnham, K. J., Djuran, M. I., Murdoch, P.dS., Ranford, J. D. & Sadler, P. J. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg. Chem. 35, 1065 (1996).","journal-title":"Inorg. Chem."},{"key":"64295_CR20","doi-asserted-by":"crossref","unstructured":"Barnham, K. J., Guo, Z. & Sadler, P. J. Stabilization of monofunctional platinum\u2013nucleotide adducts: reactions of N-acetyl-L-methionine complexes with guanosine 5\u2032-monophosphate and guanylyl(3\u2032\u20135\u2032)guanosine. J. Chem. Soc., Dalton Trans. 2867 (1996).","DOI":"10.1039\/DT9960002867"},{"key":"64295_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1021\/cr980422f","volume":"99","author":"J Reedijk","year":"1999","unstructured":"Reedijk, J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?. Chem. Rev. 99, 2499 (1999).","journal-title":"Chem. Rev."},{"key":"64295_CR22","doi-asserted-by":"crossref","unstructured":"Gibson, D. The mechanism of action of platinum anticancer agents\u2014what do we really know about it? Dalton Trans. 10681 (2009).","DOI":"10.1039\/b918871c"},{"key":"64295_CR23","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1021\/jm900138u","volume":"52","author":"Y Kasherman","year":"2009","unstructured":"Kasherman, Y., Sturup, S. & Gibson, D. Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. J. Med. Chem. 52, 4319 (2009).","journal-title":"J. Med. Chem."},{"key":"64295_CR24","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1021\/ac200861k","volume":"83","author":"H Li","year":"2011","unstructured":"Li, H. et al. Mass spectrometry evidence for cisplatin as a protein cross-linking reagent. Anal. Chem. 83, 5369 (2011).","journal-title":"Anal. Chem."},{"key":"64295_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1021\/acschembio.7b00553","volume":"12","author":"RM Cunningham","year":"2017","unstructured":"Cunningham, R. M. & DeRose, V. J. Platinum binds proteins in the endoplasmic reticulum of S. cerevisiae and induces endoplasmic reticulum stress. ACS Chem. Biol. 12, 2737 (2017).","journal-title":"ACS Chem. Biol."},{"key":"64295_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ccr.2017.02.012","volume":"352","author":"M Wenzel","year":"2017","unstructured":"Wenzel, M. & Casini, A. Mass spectrometry as a powerful tool to study therapeutic metallodrugs speciation mechanisms: current frontiers and perspectives. Coord. Chem. Rev. 352, 432 (2017).","journal-title":"Coord. Chem. Rev."},{"key":"64295_CR27","doi-asserted-by":"publisher","first-page":"118984","DOI":"10.1016\/j.ica.2019.118984","volume":"498","author":"EC Sutton","year":"2019","unstructured":"Sutton, E. C., McDevitt, C. E., Yglesias, M. V., Cunningham, R. M. & DeRose, V. J. Tracking the cellular targets of platinum anticancer drugs: current tools and emergent methods. Inorg. Chim. Acta 498, 118984 (2019).","journal-title":"Inorg. Chim. Acta"},{"key":"64295_CR28","doi-asserted-by":"publisher","first-page":"12109","DOI":"10.1021\/jacs.9b05550","volume":"141","author":"A Lasorsa","year":"2019","unstructured":"Lasorsa, A. et al. Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs. J. Am. Chem. Soc. 141, 12109 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"64295_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1039\/D3CB00042G","volume":"4","author":"X Wang","year":"2023","unstructured":"Wang, X., Zhang, Y. & Wang, C. Discovery of cisplatin-binding proteins by competitive cysteinome profiling. RSC Chem. Biol. 4, 670 (2023).","journal-title":"RSC Chem. Biol."},{"key":"64295_CR30","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.1039\/D3CC03340F","volume":"59","author":"PD O\u2019Dowd","year":"2023","unstructured":"O\u2019Dowd, P. D., Sullivan, G. P., Rodrigues, D. A., Chonghaile, T. N. & Griffith, D. M. First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins. Chem. Commun. 59, 12641 (2023).","journal-title":"Chem. Commun."},{"key":"64295_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/377649a0","volume":"377","author":"PM Takahara","year":"1995","unstructured":"Takahara, P. M., Rosenzweig, A. C., Frederick, C. A. & Lippard, S. J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377, 649 (1995).","journal-title":"Nature"},{"key":"64295_CR32","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1073\/pnas.0737293100","volume":"100","author":"J Reedijk","year":"2003","unstructured":"Reedijk, J. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. Proc. Natl Acad. Sci. USA 100, 3611 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64295_CR33","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1002\/anie.201607380","volume":"55","author":"X Shu","year":"2016","unstructured":"Shu, X., Xiong, X., Song, J., He, C. & Yi, C. Base-resolution analysis of cisplatin\u2013DNA adducts at the genome scale. Angew. Chem. Int. Ed. 55, 14246 (2016).","journal-title":"Angew. Chem. Int. Ed."},{"key":"64295_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1046\/j.1471-4159.2001.00113.x","volume":"76","author":"FC Lam","year":"2001","unstructured":"Lam, F. C. et al. \u03b2-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121 (2001).","journal-title":"J. Neurochem."},{"key":"64295_CR35","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone, T. C., Suntharalingam, K. & Lippard, S. J. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116, 3436 (2016).","journal-title":"Chem. Rev."},{"key":"64295_CR36","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1021\/cr4004314","volume":"114","author":"JJ Wilson","year":"2014","unstructured":"Wilson, J. J. & Lippard, S. J. Synthetic methods for the preparation of platinum anticancer complexes. Chem. Rev. 114, 4470 (2014).","journal-title":"Chem. Rev."},{"key":"64295_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19325-x","volume":"8","author":"AK Nanayakkara","year":"2018","unstructured":"Nanayakkara, A. K. et al. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug-resistant tumor cells. Sci. Rep. 8, 967 (2018).","journal-title":"Sci. Rep."},{"key":"64295_CR38","first-page":"383","volume":"25","author":"O Wesolowska","year":"2005","unstructured":"Wesolowska, O. et al. Human sarcoma cell lines MES-SA and MES-SA\/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res. 25, 383 (2005).","journal-title":"Anticancer Res."},{"key":"64295_CR39","first-page":"4091","volume":"45","author":"WG Harker","year":"1985","unstructured":"Harker, W. G. & Sikic, B. I. Multidrug (Pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 45, 4091 (1985).","journal-title":"Cancer Res."},{"key":"64295_CR40","first-page":"2594","volume":"47","author":"SEL Mirski","year":"1987","unstructured":"Mirski, S. E. L., Gerlach, J. H. & Cole, S. P. C. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47, 2594 (1987).","journal-title":"Cancer Res."},{"key":"64295_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SPC Cole","year":"1992","unstructured":"Cole, S. P. C. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650 (1992).","journal-title":"Science"},{"key":"64295_CR42","doi-asserted-by":"publisher","first-page":"11987","DOI":"10.1073\/pnas.1207670109","volume":"109","author":"GY Park","year":"2012","unstructured":"Park, G. Y., Wilson, J. J., Song, Y. & Lippard, S. J. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc. Natl Acad. Sci. USA 109, 11987 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64295_CR43","first-page":"1967","volume":"41","author":"T Tsuruo","year":"1981","unstructured":"Tsuruo, T., Iida, H., Tsukagoshi, S. & Sakurai, Y. Overcoming of vincristine resistance in p388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967 (1981).","journal-title":"Cancer Res."},{"key":"64295_CR44","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"64295_CR45","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-15-0335","volume":"21","author":"WC Reinhold","year":"2015","unstructured":"Reinhold, W. C., Sunshine, M., Varma, S., Doroshow, J. H. & Pommier, Y. Using cellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60. Clin. Cancer Res. 21, 3841 (2015).","journal-title":"Clin. Cancer Res."},{"key":"64295_CR46","first-page":"83","volume":"7","author":"R Kapoor","year":"1995","unstructured":"Kapoor, R., Slade, D. L., Fujimori, A., Pommier, Y. & Harker, W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7, 83 (1995).","journal-title":"Oncol. Res."},{"key":"64295_CR47","first-page":"1339","volume":"55","author":"A Fujimori","year":"1995","unstructured":"Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y. & Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM\/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55, 1339 (1995).","journal-title":"Cancer Res."},{"key":"64295_CR48","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1073\/pnas.1210419110","volume":"110","author":"JR Pritchard","year":"2013","unstructured":"Pritchard, J. R. et al. Defining principles of combination drug mechanisms of action. Proc. Natl Acad. Sci. USA 110, E170 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64295_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nchembio.503","volume":"7","author":"H Jiang","year":"2011","unstructured":"Jiang, H., Pritchard, J. R., Williams, R. T., Lauffenburger, D. A. & Hemann, M. T. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol. 7, 92 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"64295_CR50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno, P. M. et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 461 (2017).","journal-title":"Nat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64295-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T23:02:24Z","timestamp":1761346944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64295"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64295-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.W., J.B., S.J.L. and \u00d6.H.Y. declare the following competing financial interest(s): Patent applications have been filed for this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9263"}}